HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NRC
National Research Corporation
There isn't enough reported data to score NRC yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NRC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Weak |
NRC's cash flow is currently strong, and its revenue and profitability are stable, but its balance sheet is weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NRC PE Valuation
NRC has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NRC Forward outlook
There aren't enough analyst estimates for NRC to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
NRC has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus NRC down 39%.
NRC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | $0.69 | -39% |
| Q2 2025 | $0.75 | -38% |
| Q1 2025 | $1.02 | -18% |
| Q4 2024 | $1.04 | -17% |
| Q3 2024 | $1.13 | -2.6% |
| Q2 2024 | $1.21 | +3.4% |
| Q1 2024 | $1.24 | +2.5% |
| Q4 2023 | $1.25 | -1.6% |
NRC's earnings per share have fallen from their peak: $0.69 over the past year, against $1.47 in late 2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NRC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
NRC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $38.4M | +11% |
| Q2 2026 | $35.4M | +4% |
| Q1 2026 | $34.8M | +3.7% |
| Q4 2025 | $35.2M | -4.6% |
| Q3 2025 | $34.6M | -3.4% |
| Q2 2025 | $34M | -2.8% |
| Q1 2025 | $33.6M | -5% |
| Q4 2024 | $36.9M | -2.9% |
NRC's revenue has held roughly level: $38M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +0.8 points |
| Q2 2026 | -9.2% | -14 points |
| Q1 2026 | 16% | -9.6 points |
| Q4 2025 | 13% | -13 points |
| Q3 2025 | 22% | +0.1 points |
| Q2 2025 | 4.7% | -21 points |
| Q1 2025 | 26% | +0.8 points |
| Q4 2024 | 26% | -4.8 points |
NRC has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over NRC on cash flow, with more consistent year-over-year improvement.
NRC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $7M | -31% |
| Q2 2026 | $62K | +$4.2M |
| Q1 2026 | $5.3M | +46% |
| Q4 2025 | $6.1M | +213% |
| Q3 2025 | $10.2M | +30% |
| Q2 2025 | -$4.1M | -374% |
| Q1 2025 | $3.7M | -54% |
| Q4 2024 | $1.9M | -76% |
NRC still generates free cash flow, though less than at its 2020 peak: $18M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NRC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NRC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -122K shares |
| 1 year | -1.1% | -243K shares |
| 3 years | -11% | -2.8M shares |
| 5 years | -15% | -3.8M shares |
| Available history | -13% | -3.1M shares |
NRC has 22M diluted shares, down 1.1% from a year ago, with $26M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $16M |
| Q2 2026 | $7.6M |
| Q1 2026 | $1.9M |
| Q4 2025 | $1,000 |
| Q3 2025 | $9.3M |
| Q2 2025 | $6M |
| Q1 2025 | $4.9M |
| Q4 2024 | $7.4M |
NRC spent $26M buying back its own shares over the past year, down 7.3% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NRC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.1x | High |
| Q2 2026 | 3.7x | Elevated |
| Q1 2026 | 2.6x | Moderate |
| Q4 2025 | 2.4x | Moderate |
| Q3 2020 | 0.1x | Very low |
| Q2 2020 | 0.4x | Very low |
| Q1 2020 | 0.4x | Very low |
| Q4 2019 | 0.3x | Very low |
NRC's net debt is about 4.1 years of its operating earnings (EBITDA), up from less than a year a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NRC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 72.6 | Overbought |
| Stochastic | 87.0 | Overbought |
NRC's weekly RSI is 73 (overbought) and its Stochastic is 87 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NRC PE vs Healthcare Sector
| Metric | NRC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NRC has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NRC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $22.3 | 19% above |
| 20 week MA | $21.7 | 23% above |
| 50 week MA | $19.3 | 38% above |
| 100 week MA | $17.0 | 56% above |
| 200 week MA | $26.4 | 0.9% above |
NRC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
NRC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.6 | $44.4 | -33% |
| 2021 | $44.4 | $41.5 | -6.5% |
| 2022 | $41.5 | $37.3 | -10% |
| 2023 | $37.3 | $39.6 | +6.1% |
| 2024 | $39.6 | $17.4 | -56% |
| 2025 | $17.4 | $18.7 | +7.1% |
| 2026 YTD | $18.7 | $26.6 | +43% |
NRC has the edge over HIMS on returns for 2026, with the stronger performance.